Blog

Themed Salon | Antibody Discovery: The First Step in Developing Novel Antibody Drugs

Release Date:

2023-09-08 13:36

Introduction to the Themed Salon

 

Antibody drugs currently represent the fastest-growing segment within the biopharmaceutical industry and are a major focus of global drug research and development. The rapid advancement of antibody therapeutics has been driven by technological innovations, such as: Various display technologies, transgenic humanized animals, single-cell PCR, and single-cell sequencing Wait.

 

The first session, hosted by Shanghai Heyan Biotechnology Co., Ltd. and co-organized by Shanghai Municipal School of Pharmacy, Shanghai Hycells Biotechnology Co., Ltd., and the Pharmaceutical Source Research & Development Workshop, is free of charge. Thematic Salon—Antibody Discovery: The First Step in Developing Novel Antibody Drugs The event will be held in Shanghai on the afternoon of September 16, 2023. Industry peers and R&D professionals in the fields of antibody discovery and new drug development are warmly invited to register and participate, so that we can jointly explore the research and development of antibody therapeutics.

 

Salon Schedule (September 16)

Antibody Discovery: The First Step in Developing Novel Antibody Therapeutics

13:30–14:00 Registration

14:00–14:10 Event Introduction

 

01

14:10-14:40

Cell Therapy and CAR-T–Related Antibody Discovery

Wang Peng, Founder of Xichang Bio

02

14:40-15:20

Development and Application of Phage Display Technology

Zhou Chen, Founder of Shuangzhan Bio

 

15:20–15:40 Tea Break

 

03

15:40-16:20

Progress in the Development and Application Research of Nanobody Technology

Li Shenghua, Chief Scientist, NuAnBo Biotechnology

04

16:20-16:40

Multi-species gene-edited animals

Empowering Antibody Drug Discovery

Zhang Jiwei, CEO

Previous page

Issue 1 | Sharing of CAR Positive Rate Testing Data

Hycells Services | “True” Viral Neutralizing Antibody Testing

Next page

Related News

(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.

(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.

Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.

A novel mechanism by which iron overload in the tumor microenvironment triggers ferroptosis in CD8⁺ T cells | Guangzhou National Laboratory publishes in Nature Communications, revealing a key pathway of immune evasion (IF: 18.2)

Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.

Hycells Recruitment | Never Stop Exploring, Never Stop Innovating

The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.

3.0 High-Efficiency Version of HiXpan® NK Serum-Free Culture Kit | Chapter 4: Comprehensive Overview of Customer-Specific Culture Data Across Multiple Scenarios

The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.